Cargando…
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
BACKGROUND: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). METHODS: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217655/ https://www.ncbi.nlm.nih.gov/pubmed/35238940 http://dx.doi.org/10.1093/ndt/gfac040 |